An expert in hepatitis delta virus said Vir Biotechnology Inc.’s phase II findings with the monoclonal antibody tobevibart and the small interfering ribonucleic acid elebsiran in chronic disease could lead to a “change [in] the entire care cascade and paradigm.” Shares of Vir (NASDAQ:VIR) ended June 5 at $12.66, up $2.08, or 19.7%, on the clinical news. Read More
Amgen Inc. is looking to position inebilizumab as the first therapeutic specifically for treating immunoglobulin G4-related disease (IgG4-RD), a rare, immune-mediated condition that can affect multiple organs, after yielding what Leerink Partners analyst David Risinger called “exceptional” phase III results. Read More
The discussion that preceded the June 4 U.S. FDA advisory committee vote against the approval of Lykos Therapeutics Inc.’s midomafetamine as a treatment for post-traumatic stress disorder could shine some light on the way forward for other sponsors developing psychedelics for approved medical use. Read More
Life sciences venture capital company, Brandon Capital, announced the first close of its sixth fund for AU$270 million (US$180 million) during the 2024 Biotechnology Innovation Organization International Convention in San Diego. Fund VI will see Brandon Capital continue to seed new Australian and New Zealand life sciences startups, as well as advance its expansion into international markets, particularly in the U.K., Europe, and the U.S. Read More
Fibrodysplasia ossificans progressiva (FOP) is a rare and life-threatening genetic disease caused by gain-of-function mutations in the ALK2 gene, which encodes activin receptor-like kinase 2. Blueprint Medicines Corp. has elucidated the discovery of their ALK2 inhibitor BLU-782, which is now in phase II studies at Ipsen SA for the treatment of FOP. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Annexon, Bridgebio, Capricor, Crinetics, Eledon, Equillium, Glycomimetics, Innate, Lumos, OS Therapies, Pharvaris, Rhythm, Valneva, Viking, Zevra. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aeterna, Alphamab, Alveolix, Arrivent, Astrazeneca, Biolojic, Ceapro, Epiendo, Fusion, HMNC, Immunitybio, Ladrx, Merck, Nantcell, Spruce. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Be Biopharma, Neoimmune. Read More
